Plasma β-Amyloids and Tau Proteins in Patients with Vascular Cognitive Impairment
- 554 Downloads
Increases in plasma of β-amyloids (Aβ) and tau proteins have been noted in patients with Alzheimer’s dementia (AD). Our study investigated the associations of plasma Aβ and tau proteins with dementia in stroke patients. This cross-sectional study recruited 24 controls (mean age: 67.4 ± 7.5 years, 33.3% male), 27 stroke patients without dementia (mean age: 70.7 ± 6.9 years, 60.7% male), 34 stroke patients with dementia (mean age: 78.3 ± 5.3 years, 45.5% male, Clinical Dementia Ranking (CDR): 1.46 ± 0.63), and 21 AD patients (mean age: 77.1 ± 9.1 years, 42.9% male, CDR: 1.43 ± 0.60) from a medical center. Dementia was defined as a CDR scale score of ≥ 1. The plasma levels of Aβ-40, Aβ-42, and tau were analyzed using immunomagnetic reduction. One-way analysis of variance was used to compare the differences in measured protein levels between the groups. The results indicated that plasma levels of tau and Aβ-42, but not Aβ-40, in stroke patients were significantly higher than in the controls. After adjustment for age, sex, diabetes mellitus, hypertension, and hyperlipidemia, only plasma level of Aβ-42 remained significantly higher in stroke patients with dementia than in those without dementia (OR 1.85, 1.25–2.75, p = 0.002). In summary, our results suggest that plasma Aβ-42 is a potential biomarker for dementia in stroke patients.
KeywordsStroke Vascular dementia Amyloid beta Tau protein
The authors thank the 3rd core facility at National Taiwan University Hospital for support.
This work was supported by Taiwan Ministry of Science and Technology Grant (105-2314-B-002-001).
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- Chiu, M. J., Yang, S. Y., Horng, H. E., Yang, C. C., Chen, T. F., Chieh, J. J., et al. (2013). Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer’s disease. ACS Chemical Neuroscience, 4(12), 1530–1536. https://doi.org/10.1021/cn400129p.CrossRefPubMedPubMedCentralGoogle Scholar
- Huang, K. L., Lin, K. J., Ho, M. Y., Chang, Y. J., Chang, C. H., Wey, S. P., et al. (2012). Amyloid deposition after cerebral hypoperfusion: Evidenced on [(18)F]AV-45 positron emission tomography. Journal of the Neurological Sciences, 319(1–2), 124–129. https://doi.org/10.1016/j.jns.2012.04.014.CrossRefPubMedGoogle Scholar
- Jack, C. R. Jr., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., et al. (2011). Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 257–262. https://doi.org/10.1016/j.jalz.2011.03.004.CrossRefGoogle Scholar
- Tang, S. C., Wang, Y. C., Li, Y. I., Lin, H. C., Manzanero, S., Hsieh, Y. H., et al. (2013). Functional role of soluble receptor for advanced glycation end products in stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(3), 585–594. https://doi.org/10.1161/atvbaha.112.300523.CrossRefPubMedGoogle Scholar
- Yang, S. Y., Chiu, M. J., Chen, T. F., Lin, C. H., Jeng, J. S., Tang, S. C., et al. (2017). Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases. Scientific Reports, 7(1), 9304. https://doi.org/10.1038/s41598-017-09009-3.CrossRefPubMedPubMedCentralGoogle Scholar